Gilead Sciences Q1 EPS Estimate Raised by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research increased their Q1 2028 EPS estimates for Gilead Sciences in a research note issued to investors on Tuesday, September 1st. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings per share of $2.15 for the quarter, up from their previous forecast of $2.14. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is ($0.47) per share. Zacks Research also issued estimates for Gilead Sciences’ Q2 2028 earnings at $2.31 EPS and FY2028 earnings at $9.66 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, beating the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.01 earnings per share.

Several other analysts have also recently weighed in on GILD. Rothschild & Co Redburn dropped their price objective on shares of Gilead Sciences from $170.00 to $167.00 in a research note on Monday, May 11th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research report on Wednesday, May 20th. Royal Bank Of Canada boosted their price target on Gilead Sciences from $120.00 to $123.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Barclays reduced their price objective on shares of Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 29th. Finally, Morgan Stanley cut their price target on shares of Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating for the company in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $158.04.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $149.61 on Thursday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm has a market cap of $185.51 billion, a price-to-earnings ratio of -56.03 and a beta of 0.33. The stock’s fifty day moving average price is $135.66 and its two-hundred day moving average price is $136.45. Gilead Sciences has a one year low of $108.46 and a one year high of $157.29.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Aviva PLC raised its holdings in shares of Gilead Sciences by 5.4% in the 4th quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock worth $141,978,000 after purchasing an additional 59,782 shares during the period. Life Cycle Investment Partners Ltd purchased a new position in Gilead Sciences in the 4th quarter valued at approximately $1,418,000. Bank of Nova Scotia purchased a new position in shares of Gilead Sciences in the second quarter valued at $100,056,000. OMERS ADMINISTRATION Corp purchased a new position in Gilead Sciences during the 2nd quarter valued at about $55,754,000. Finally, Harvest Fund Management Co. Ltd grew its stake in Gilead Sciences by 14.4% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock valued at $13,075,000 after acquiring an additional 13,385 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director directly owned 10,066 shares in the company, valued at approximately $1,459,771.32. This represents a 33.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $148.64, for a total transaction of $2,229,600.00. Following the completion of the sale, the chief executive officer directly owned 577,133 shares of the company’s stock, valued at approximately $85,785,049.12. This trade represents a 2.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock valued at $14,495,820 over the last ninety days. Insiders own 0.30% of the company’s stock.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Zacks upgraded Gilead to a “Strong Buy” rating. The upgrade reflects improving expectations for the company’s earnings outlook and may support investor demand. Gilead Upgraded to Strong Buy
• Positive Sentiment: Zacks raised its 2027 EPS forecasts for every quarter and the full year. Estimates now range from $2.09 in Q1 to $2.60 in Q4, with full-year 2027 EPS lifted to $9.36 from $9.30. The revisions indicate modestly stronger anticipated profitability. Zacks Gilead Forecasts
• Positive Sentiment: FDA approval of Bixlenvo expands Gilead’s HIV portfolio. The single-tablet treatment targets underserved patients and could create an additional growth opportunity, although sales adoption and competitive dynamics remain important factors. Bixlenvo HIV Growth Opportunity
• Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares valued at approximately $2.23 million. The sale reduced his direct ownership by 2.53%, but it was conducted under a pre-arranged Rule 10b5-1 trading plan, making it a limited bearish signal. SEC Insider Trading Filing
• Neutral Sentiment: Gilead reaffirmed its quarterly dividend of $0.82 per share. The $3.28 annualized payout provides income support, though the reported negative payout ratio reflects unusual earnings effects and may limit its immediate impact on trading.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.